U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 441 - 450 of 13408 results

Status:
Investigational
Source:
INN:levopropicillin [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Levopropylcillin – is a penicillin derivative, L-enantiomer of antibiotic Propicillin. Levopropylcillin properties are similar to benzylpenicillin particularly used in streptococcal infections, not resistant to penicillinase. Levopropylcillin is acid resistant and can be used orally as the potassium salt.
Status:
Investigational
Source:
INN:zibrofusidic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:lanicemine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lanicemine is a low-trapping NMDA channel blocker, which was developed by Fisons Pharmaceuticals and later by AstraZeneca for the treatment of the major depressive disorder. The development was terminated in phase II as the drug did not meet the primary endpoint.
Status:
Investigational
Source:
INN:itrocinonide
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

ITROCINONIDE is a synthetic corticosteroid which showed no signs of systemic activity (cortisol depression).
Status:
Investigational
Source:
INN:isbufylline
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Isbufylline is a xanthine derivative. This compound exhibits remarkable antibronchospastic properties both in in vitro and in vivo (after oral or intravenous administration) experimental models. Isbufylline is significantly more effective than theophylline in antagonizing bronchospasms elicited by spasmogens (capsaicin, arachidonic acid, PAF and antigen) which mainly act by a local release of biologically active substances proposed to be involved in the pathogenesis of asthma. Isbufylline, unlike theophylline, possesses little or no CNS excitatory properties. Isbufylline exerts a greater inhibitory activity than theophylline on total phosphodiesterase activity in the rat lung.
Status:
Investigational
Source:
INN:cilofungin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

ilofungin is a narrow spectrum antimycotic patented by a pharmaceutical company Eli Lilly and Co in 1981. Cilofungin is particularly active against the opportunistic fungal pathogen Candida albicans. Cilofungin action is exerted through inhibition of the synthesis of (1,3)-beta-glucan, an essential cell wall component, it invades a fungus' ability to synthesize cell walls.
Status:
Investigational
Source:
INN:isoprednidene
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

ISOPREDNIDENE is a synthetic glucocorticoid. It suppresses both the release and the synthesis of adrenocorticotropin by the pituitary gland.
Status:
Investigational
Source:
INN:pleuromulin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Conditions:

Pleuromulin (pleuromulitin) is a natural antibiotic isolated from Basidiomycete Pleurotus. Pleuromulitin exhibits activity mainly against gram-positive bacteria including S. aureus, Klebasiella pneumoniae and Bacillus Subtilis. Pleuromulin is an organic compound which is not reported to be used in as a drug however its derivatives have been used in treatment of infections. The first pleuromulitin that was approved in 1979 for use in veterinary medicine was semi-synthetic derivative tiamulin. Semisynthetic pleuromutilin retapamulin (ALTABAX, GlaxoSmithKline) was the first approved for topical use in humans in 2007. Another derivative of pleuromulin, Lefamulin has been successfully tested in phase 1 clinical trial for systemic use in patients (Nabriva Therapeutics AG).
Status:
Investigational
Source:
INN:mivobulin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Mivobulin is a synthetic water-soluble colchicine analog with the broad antitumor activity that competitively binds tubulin at the colchicine-binding site and inhibits tubulin polymerization. Cancer cells exposed to Mivobulin isethionate accumulate in the M phase of the cell cycle and subsequently die. Preclinical studies have demonstrated that Mivobulin isethionate is able to cross the blood-brain barrier. Importantly, Mivobulin isethionate demonstrated significant antitumor activity in a broad spectrum of murine and human tumor models that were cross-resistant to vincristine, cisplatin, vinblastine, navelbine, and doxorubicin and in tumor cell lines exhibiting multidrug resistance owing to P-glycoprotein overexpression. In animal studies, the activity of Mivobulin isethionate was largely independent of the route of drug administration but favored a prolonged treatment schedule. Unfortunately, in clinical trials, Mivobulin fail to demonstrate the significant activity
Status:
Investigational
Source:
NCT04669587: Phase 1/Phase 2 Interventional Recruiting Estrogen Receptor-Positive
(2021)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)